Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
NCT03801499
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Protocol modification
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG:
Lenvatinib
Sponsor
Sun Yat-sen University